CONCORDBIO1,445.20

Concord Biotech Ltd.

· Pharma & Health
AnnualQuarterly₹ CrorePeersBIOCONDIVISLABCAPLIPOINTEMCUREBLUEJETERISGRANULESACUTAASMcap ₹15,119 Cr
View
In ₹ Crore except Per Share
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Revenue from Operations1,016.91,200.11,054.91,108.4
Other Income33.844.452.451.5
Total Income1,050.71,244.51,107.21,159.9
Expenses
+ Cost of Materials Consumed184.5264.3254.3264.3
+ Purchases of Stock-in-Trade56.756.062.661.1
+ Changes in Inventories-12.1-14.8-71.3-70.5
+ Employee Benefit Expense123.0138.9176.9182.6
+ Finance Costs2.60.50.30.3
+ Depreciation & Amortisation53.654.474.574.8
+ Other Expenses233.1249.3264.9282.5
Total Expenses641.5748.7762.2795.1
EBITDA431.6506.3367.4388.4
EBIT378.0452.0292.9313.6
Profit
PBT before Exceptional Items409.2495.9345.0364.8
+ Exceptional Items0.00.0-3.3-3.3
Pretax Income409.2495.9341.7361.6
+ Current Tax99.8119.086.392.6
+ Deferred Tax4.63.9-0.9-1.2
Tax Expense104.5122.985.491.4
+ Share of Associates & JVs3.4-1.32.92.7
Net Income308.1371.6259.2272.9
+ Net Income — Continuing Ops304.7373.0256.3270.2
+ Other Comprehensive Income-0.06.055.275.1
Total Comprehensive Income308.1377.6314.5348.0
Net Income to Common308.1371.6260.9275.4
Minority Interest0.0-1.7-2.5
Per Share
Basic EPS29.4535.5224.7826.09
Diluted EPS29.4535.5224.7826.09
Other Comprehensive Income — detail
+ Other Comprehensive Income6.055.275.1
+ Items NOT to be Reclassified to P&L-0.06.055.875.6
+ Tax on Items NOT to be Reclassified0.00.50.4
+ Items to be Reclassified to P&L0.0-0.2
Comprehensive Income — Owners of Parent-0.0377.6316.3287.0
Comprehensive Income — Non-controlling Interests0.00.0-1.8-2.1
Per Share — as-filed variants
Basic EPS — Continuing Operations29.4535.5224.7826.09
Diluted EPS — Continuing Operations29.4535.5224.7826.09
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit787.7894.6809.2853.5
Gross Margin %77.4674.5476.7177.01
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)409.2495.9345.0364.8
− Exceptional Items (reconciliation)0.00.0-3.3-3.3
Net Income Adj (tax-effected)308.1371.6261.7275.3
EPS Adj29.4535.5225.0126.32
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value1.001.001.001.00
Paid Up Equity Capital10.510.510.510.5
As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.